Literature DB >> 9425944

Precore wild-type DNA and immune complexes persist in chronic hepatitis B after seroconversion: no association between genome conversion and seroconversion.

T Maruyama1, S Kuwata, K Koike, S Iino, K Yasuda, H Yotsuyanagi, K Moriya, H Maekawa, H Yamada, Y Shibata, D R Milich.   

Abstract

Precore hepatitis B virus (HBV) mutants may gradually prevail during or after seroconversion (SC) from hepatitis B e antigen (HBeAg) to hepatitis B e antigen antibody (anti-HBe) status in many chronic hepatitis B (CH-B) patients. However, patients with CH-B still produce anti-HBe more than several years after SC, and the relationship between SC and genome conversion in the precore region has not been clarified. Therefore, in patients with CH-B who had a sustained loss of HBeAg and complete remission of hepatitis after SC, the precore region was sequenced in paired serum samples from 1 year before SC to 3 years after SC. Mutant precore defective HBV DNA was found in only 6 (19%) of 31 CH-B patients who had a complete remission of hepatitis after SC. Mixed-type HBV DNA (precore wild-type and mutant-type) was found in 4 (13%) patients. Wild-type HBV DNA was found in 21 (68%) CH-B patients after SC. Longer-term follow-up of 11 CH-B patients indicated that 3 of 11 patients experienced precore genome conversion 2 to 3 years after SC. E-plus DNA or e-minus DNA was semiquantitated by polymerase chain reaction (PCR) and restriction fragment length polymorphism (RFLP) assays before and after SC. E-plus DNA levels decreased from 10(5.56+/-1.58) to 10(2.45+/-1.61). Similarly, e-minus DNA levels declined from 10(4.25+/-1.56) to 10(1.86+/-1.37). By dot-blot assay, serum HBV DNA became negative soon after SC, as did serum HBeAg. In contrast, HBeAg-containing immune complexes were still detected after SC. Anti-HBe antibody was produced throughout SC and thereafter, as determined by a sensitive experimental assay. Therefore, we conclude that genome-conversion in the precore region is a separate event from HBeAg/anti-HBe seroconversion.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9425944     DOI: 10.1002/hep.510270137

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  3 in total

1.  Effect of lamivudine in HBeAg-positive chronic hepatitis B: discordant effect on HBeAg and HBV DNA according to pretreatment ALT level.

Authors:  Tomoko Kurihara; Fumio Imazeki; Osamu Yokosuka; Kenichi Fukai; Tatsuo Kanda; Shigenobu Kawai; Hiromitsu Saisho
Journal:  World J Gastroenterol       Date:  2005-06-14       Impact factor: 5.742

Review 2.  Molecular characteristics and stages of chronic hepatitis B virus infection.

Authors:  Ying-Hui Shi; Chang-He Shi
Journal:  World J Gastroenterol       Date:  2009-07-07       Impact factor: 5.742

3.  Mechanisms downstream of reverse transcription reduce serum levels of HBV DNA but not of HBsAg in chronic hepatitis B virus infection.

Authors:  Simon B Larsson; Sebastian Malmström; Charles Hannoun; Gunnar Norkrans; Magnus Lindh
Journal:  Virol J       Date:  2015-12-09       Impact factor: 4.099

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.